GT Biopharma (GTBP) vs Kyntra Bio (KYNB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GT Biopharma (GTBP) has outperformed Kyntra Bio (KYNB) over the past year, gaining 303.3% versus a loss of 81.5%. Over five years, GTBP leads with a -97.8% price change compared with -99.5% for KYNB. GT Biopharma is the larger company by market cap ($6.3 million vs $6.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GTBP | KYNB |
|---|---|---|
| Share price | $2.96 | $1.56 |
| Market cap | $6.33M | $6.32M |
| 1-day change | -6.92% | -13.33% |
| YTD return | +277.07% | -82.23% |
| 1-year return | +303.27% | -81.47% |
| 5-year return | -97.77% | -99.49% |
| EPS (TTM) | $-128.61 | $-4.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.44M |
| Revenue growth (YoY) | — | -78.26% |
| Net income (latest FY) | $-28.35M | $183.45M |
| Gross margin | — | 91.37% |
| Operating margin | — | -712.66% |
| Net margin | — | 2848.63% |
| 52-week high | $23.60 | $10.47 |
| 52-week low | $2.87 | $1.56 |
| Distance from 52-week high | -87.46% | -85.10% |
| Analyst consensus | none | none |
| Avg. price target upside | +2433.78% | +2442.95% |
| Average volume | 78.16K | 29.96K |
| Shares outstanding | 2.14M | 4.05M |
| Employees | 1 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed KYNB by 384.7 percentage points over the past year.
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
GTBP vs KYNB FAQ
Which is bigger, GT Biopharma or Kyntra Bio?
GT Biopharma (GTBP) is larger, with a market capitalization of $6.33M compared with $6.32M for Kyntra Bio (KYNB).
Which stock has performed better over the past year, GTBP or KYNB?
GTBP returned +303.27% over the past 12 months, compared with -81.47% for KYNB (price return, excluding dividends). Past performance does not predict future results.
Are GT Biopharma and Kyntra Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.